293 related articles for article (PubMed ID: 22180496)
41. Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2'-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs.
Preston TJ; Henderson JT; McCallum GP; Wells PG
Mol Cancer Ther; 2009 Jul; 8(7):2015-26. PubMed ID: 19567822
[TBL] [Abstract][Full Text] [Related]
42. Diazido mixed-amine platinum(IV) anticancer complexes activatable by visible-light form novel DNA adducts.
Zhao Y; Woods JA; Farrer NJ; Robinson KS; Pracharova J; Kasparkova J; Novakova O; Li H; Salassa L; Pizarro AM; Clarkson GJ; Song L; Brabec V; Sadler PJ
Chemistry; 2013 Jul; 19(29):9578-91. PubMed ID: 23733242
[TBL] [Abstract][Full Text] [Related]
43. Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin.
Cenni B; Kim HK; Bubley GJ; Aebi S; Fink D; Teicher BA; Howell SB; Christen RD
Br J Cancer; 1999 May; 80(5-6):699-704. PubMed ID: 10360646
[TBL] [Abstract][Full Text] [Related]
44. Cisplatin.
Trimmer EE; Essigmann JM
Essays Biochem; 1999; 34():191-211. PubMed ID: 10730196
[TBL] [Abstract][Full Text] [Related]
45. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system.
Perego P; Caserini C; Gatti L; Carenini N; Romanelli S; Supino R; Colangelo D; Viano I; Leone R; Spinelli S; Pezzoni G; Manzotti C; Farrell N; Zunino F
Mol Pharmacol; 1999 Mar; 55(3):528-34. PubMed ID: 10051537
[TBL] [Abstract][Full Text] [Related]
46. Interaction of 11 cisplatin analogues with DNA: characteristic pattern of damage with monofunctional analogues.
Murray V; Whittaker J; Temple MD; McFadyen WD
Biochim Biophys Acta; 1997 Nov; 1354(3):261-71. PubMed ID: 9427535
[TBL] [Abstract][Full Text] [Related]
47. Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro.
Kostrhunova H; Vrana O; Suchankova T; Gibson D; Kasparkova J; Brabec V
Chem Res Toxicol; 2010 Nov; 23(11):1833-42. PubMed ID: 20939593
[TBL] [Abstract][Full Text] [Related]
48. Preparation of mammalian expression vectors incorporating site-specifically platinated-DNA lesions.
Ang WH; Brown WW; Lippard SJ
Bioconjug Chem; 2009 May; 20(5):1058-63. PubMed ID: 19351185
[TBL] [Abstract][Full Text] [Related]
49. Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link.
Wu Y; Bhattacharyya D; King CL; Baskerville-Abraham I; Huh SH; Boysen G; Swenberg JA; Temple B; Campbell SL; Chaney SG
Biochemistry; 2007 Jun; 46(22):6477-87. PubMed ID: 17497831
[TBL] [Abstract][Full Text] [Related]
50. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
Guichard S; Arnould S; Hennebelle I; Bugat R; Canal P
Anticancer Drugs; 2001 Oct; 12(9):741-51. PubMed ID: 11593056
[TBL] [Abstract][Full Text] [Related]
51. DNA adducts from a tumorigenic metabolite of benzo[a]pyrene block human RNA polymerase II elongation in a sequence- and stereochemistry-dependent manner.
Perlow RA; Kolbanovskii A; Hingerty BE; Geacintov NE; Broyde S; Scicchitano DA
J Mol Biol; 2002 Aug; 321(1):29-47. PubMed ID: 12139931
[TBL] [Abstract][Full Text] [Related]
52. The influence of the ethane-1,2-diamine ligand on the activity of a monofunctional platinum complex.
Graziotto ME; Akerfeldt MC; Gunn AP; Yang K; Somerville MV; Coleman NV; Roberts BR; Hambley TW; New EJ
J Inorg Biochem; 2017 Dec; 177():328-334. PubMed ID: 28789807
[TBL] [Abstract][Full Text] [Related]
53. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
54. The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta.
Vaisman A; Chaney SG
J Biol Chem; 2000 Apr; 275(17):13017-25. PubMed ID: 10777605
[TBL] [Abstract][Full Text] [Related]
55. Structural and mechanistic studies of polymerase η bypass of phenanthriplatin DNA damage.
Gregory MT; Park GY; Johnstone TC; Lee YS; Yang W; Lippard SJ
Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9133-8. PubMed ID: 24927576
[TBL] [Abstract][Full Text] [Related]
56. Oxaliplatin-induced damage of cellular DNA.
Woynarowski JM; Faivre S; Herzig MC; Arnett B; Chapman WG; Trevino AV; Raymond E; Chaney SG; Vaisman A; Varchenko M; Juniewicz PE
Mol Pharmacol; 2000 Nov; 58(5):920-7. PubMed ID: 11040038
[TBL] [Abstract][Full Text] [Related]
57. Behavior of T7 RNA polymerase and mammalian RNA polymerase II at site-specific cisplatin adducts in the template DNA.
Tornaletti S; Patrick SM; Turchi JJ; Hanawalt PC
J Biol Chem; 2003 Sep; 278(37):35791-7. PubMed ID: 12829693
[TBL] [Abstract][Full Text] [Related]
58. Recognition and repair of DNA-cisplatin adducts.
Woźniak K; Błasiak J
Acta Biochim Pol; 2002; 49(3):583-96. PubMed ID: 12422229
[TBL] [Abstract][Full Text] [Related]
59. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
60. A monofunctional platinum(II)-based anticancer agent from a salicylanilide derivative: Synthesis, antiproliferative activity, and transcription inhibition.
Wang B; Wang Z; Ai F; Tang WK; Zhu G
J Inorg Biochem; 2015 Jan; 142():118-25. PubMed ID: 25450026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
